Open AccessIn vitro Anti‐tumor Activity of Anti‐c‐ erbB ‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody
Author(s) -
Sugiyama Yoshihiro,
Aihara Miki,
Shibamori Masafumi,
Deguchi Kyohei,
Imagawa Kenichi,
Kikuchi Mikio,
Momota Hiroshi,
Azuma Takachika,
Okada Hidechika,
Alper Özge,
Hitomi Jiro,
Yamaguchi Ken
Publication year - 1992
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1992.tb00126.x
Subject(s) - monoclonal antibody , immunotherapy , gene product , cancer research , cancer , antibody , in vitro , oncogene , biology , cd3 , antigen , cell , immunology , cd8 , immune system , gene , cell cycle , gene expression , biochemistry , genetics
With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐ erb B‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti‐tumor activity in vitro on a breast tumor cell line, ZR‐75–1, which expressed abundant c‐ erbB ‐2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.